CFGS
RUBY

Concourse Financial Group Securities’s Rubius Therapeutics, Inc RUBY Stock Holding History

Concourse Financial Group Securities’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-73
Closed -$542 – 2358
2019
Q4 		$1K Buy
+73
New +$706 ﹤0.01% 2026

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

Concourse Financial Group Securities's RUBY Position: Q1 2020 in Review

Concourse Financial Group Securities sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2020, closing a stake of 73 shares — an estimated $542 sold.

Concourse Financial Group Securities first reported a position in RUBY in Q4 2019 and held it in 1 quarter. The position peaked at $1K in Q4 2019. 76 funds tracked by Wall St. Rank hold RUBY as of Q1 2020.

  • Concourse Financial Group Securities reported no remaining Rubius Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
  • Concourse Financial Group Securities sold 73 Rubius Therapeutics, Inc shares in Q1 2020, an estimated $542.
  • Concourse Financial Group Securities first reported a position in Rubius Therapeutics, Inc in Q4 2019 and held it in 1 quarter.
  • Concourse Financial Group Securities's Rubius Therapeutics, Inc position peaked at $1K in Q4 2019.
  • 76 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2020.

Based on Concourse Financial Group Securities's 13F filing for Q1 2020, filed 13 May 2020.